Related Experiment Videos
Binding of hepatitis C virus to CD81
P Pileri1, Y Uematsu, S Campagnoli
1IRIS, Chiron, Siena 53100, Italy.
Science (New York, N.Y.)
|October 30, 1998
Summary
Hepatitis C virus (HCV) uses its E2 protein to bind CD81 on liver and B cells. This interaction is crucial for viral entry and can be blocked by neutralizing antibodies, offering potential therapeutic targets.
Area of Science:
- Virology
- Immunology
- Hepatology
Background:
- Chronic hepatitis C virus (HCV) infection affects 3% of the global population, leading to significant liver disease.
- HCV is linked to cryoglobulinemia, a B lymphocyte disorder, indicating a broader impact beyond the liver.
- The precise mechanisms of HCV cell entry and its tropism remain incompletely understood.
Purpose of the Study:
- To investigate the interaction between the HCV E2 envelope protein and host cell receptors.
- To identify the specific region on CD81 involved in HCV binding.
- To explore the potential of blocking this interaction as a strategy against HCV infection.
Main Methods:
- Mapping the binding site of HCV E2 protein on human CD81.
- Utilizing recombinant molecules containing the CD81 major extracellular loop.
- Assessing the effect of neutralizing antibodies on HCV-CD81 binding in vitro.
Main Results:
- The HCV E2 envelope protein specifically binds to human CD81, a tetraspanin found on hepatocytes and B lymphocytes.
- Binding was localized to the major extracellular loop of CD81.
- Antibodies known to neutralize HCV infection in vivo effectively inhibited the binding of HCV to CD81 in vitro.
Conclusions:
- CD81 serves as a key receptor for HCV entry into host cells, particularly hepatocytes and B lymphocytes.
- The E2 protein's interaction with the CD81 extracellular loop is critical for viral attachment.
- Targeting the HCV E2-CD81 interaction with neutralizing antibodies presents a promising therapeutic avenue for controlling HCV infection.